Kuano is an artificial intelligence company using quantum computing to create molecular design solutions that is headquartered in London, England and was founded in 2020 by Vid Stojevic, David Wright, Parminder Ruprah, and Jarryl D’Oyley.
Kuano focuses on developing enzyme inhibitors using artificial intelligence and quantum computing simulations for pharmaceutical, crop protection, and industrial chemistry applications. Properties of enzyme inhibitors being selected for by Kuano include enzyme binding transition states, enzyme transition state selectivity, and ability to maintain enzyme function regardless of possible mutations. Kuano manipulates enzyme properties to create enzyme inhibitors with more desirable dosage levels, toxicity levels, and resistance levels to mutations.
Kuano focuses on developing enzyme inhibitors using artificial intelligence and quantum computing simulations for pharmaceutical, crop protection, and industrial chemistry applications. Properties of enzyme inhibitors being selected for by Kuano include enzyme binding transition states, enzyme transition state selectivity, and ability to maintain enzyme function regardless of possible mutations. Kuano manipulates enzyme properties to create enzyme inhibitors with more desirable dosage levels, toxicity levels, and resistance levels to mutations.
Employees: 11-50
Total raised: $3.64M
Founded date: 2020
Investors 6
| Date | Name | Website |
| - | o2h ventur... | o2hventure... |
| - | Angel CoFu... | acfinvesto... |
| - | Syndicate ... | syndicater... |
| 10.02.2023 | Cambridge ... | cambridgea... |
| 12.06.2021 | Creative D... | creativede... |
| - | AI Seed Fu... | aiseed.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.09.2023 | Seed | $2.25M | - |
| 12.07.2021 | Seed | $1.39M | - |
Mentions in press and media 7
| Date | Title | Description |
| 13.09.2023 | Kuano Raises £1.8M in Funding | Kuano – Robert Hornby of Mercia with Vid Stoj Kuano, a Cambridge, UK-based drug discovery company combining quantum mechanics with AI to design innovative medicines, closed a £1.8m seed funding. The round was led by Mercia Ventures and incl... |
| 12.09.2023 | Kuano raises £1.8M in seed funding to accelerate quantum drug discovery | Cambridge, UK, 12 September 2023: Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, announces the close of its £1.8M seed funding round, led by Mercia Ventures, and including ACF... |
| 12.09.2023 | Kuano secures £1.8 million investment led by Mercia Ventures | - |
| 12.09.2023 | Kuano raises closes £1.8M harnessing quantum mechanics and AI for drug design | Today drug discovery company Kuano, announced the close of a £1.8 million seed funding round. The company combines quantum mechanics with AI to design the next generation of medicines, focusing on seeing and modelling enzymes. Dysfunctional... |
| 12.07.2021 | Kuano.ai Raises £1M in Seed Funding | Kuano.ai, a London, UK-based provider of a software platform for quantum modelling of enzymes, raised £1m in seed funding. Backers included ACF Investors, o2h Ventures and a syndicate of Cambridge-based angel investors. The company intends ... |
| 08.07.2021 | UK biotech startup Kuano lands £1M for AI-driven drug discovery | With artificial intelligence (AI) geared up to transform the pharmaceutical industry, a growing number of biotech and pharma startups are harnessing cutting-edge AI technology for drug discovery and drug remodelling. To shift the COVID-19 t... |
| - | UK biotech startup Kuano lands £1M for AI-driven drug discovery | With artificial intelligence (AI) geared up to transform the pharmaceutical industry, a growing number of biotech and pharma startups are harnessing cutting-edge AI technology for drug discovery and drug remodelling. To shift the COVID-19 t... |